The FDA approval of Gilead’s once-daily combination of bictegravir and lenacapavir opens a new option for the minority of patients who still take multiple HIV pills per day.
The FDA approval of Gilead’s once-daily combination of bictegravir and lenacapavir opens a new option for the minority of patients who still take multiple HIV pills per day.